Arlene Chapman to Humans
This is a "connection" page, showing publications Arlene Chapman has written about Humans.
Connection Strength
1.261
-
Pregnancy in Autosomal Dominant Polycystic Kidney Disease. Adv Kidney Dis Health. 2023 Sep; 30(5):454-460.
Score: 0.031
-
Polycystic Kidney Disease in the Real World. Kidney360. 2021 12 30; 2(12):1882-1883.
Score: 0.028
-
Agreement of Food Records and 24-Hour Urine Studies in Clinical Practice. J Ren Nutr. 2022 01; 32(1):51-57.
Score: 0.027
-
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.
Score: 0.024
-
The future of pharmacogenetics in the treatment of hypertension. Pharmacogenomics. 2019 02; 20(3):129-132.
Score: 0.023
-
Hypoxia-Inducible Factor 1a (HIF-1a), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease. Am J Nephrol. 2018; 47(4):228-230.
Score: 0.021
-
Autosomal dominant polycystic kidney disease. CMAJ. 2017 11 13; 189(45):E1396.
Score: 0.021
-
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/ß-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials. J Am Heart Assoc. 2017 Nov 02; 6(11).
Score: 0.021
-
New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017 Dec; 13(12):750-768.
Score: 0.021
-
A Patient with a Novel Gene Mutation Leading to Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 10 06; 12(10):1695-1698.
Score: 0.020
-
Gastrointestinal Manifestations of Autosomal-Dominant Polycystic Kidney Disease. Clin Gastroenterol Hepatol. 2017 01; 15(1):17-24.
Score: 0.019
-
The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol. 2017 01; 32(1):31-42.
Score: 0.019
-
A Physiologic Approach to the Pharmacogenomics of Hypertension. Adv Chronic Kidney Dis. 2016 Mar; 23(2):91-105.
Score: 0.018
-
Acute Response to Tolvaptan in ADPKD: A Window to Predict Long-term Efficacy? Am J Kidney Dis. 2015 Jun; 65(6):811-3.
Score: 0.018
-
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015 Jul; 88(1):17-27.
Score: 0.017
-
Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2014 Dec; 29(12):2194-201.
Score: 0.016
-
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens. 2014 Apr; 27(4):546-54.
Score: 0.015
-
The fetal environment: a critical phase that determines future renal outcomes in autosomal dominant polycystic kidney disease. Kidney Int. 2012 May; 81(9):814-5.
Score: 0.014
-
Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012 Mar; 7(3):479-86.
Score: 0.014
-
Imaging approaches to patients with polycystic kidney disease. Semin Nephrol. 2011 May; 31(3):237-44.
Score: 0.013
-
Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis. 2010 Mar; 17(2):153-63.
Score: 0.012
-
The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol. 2010 Jan; 5(1):102-9.
Score: 0.012
-
Polycystic kidney disease: The cadence of kidney growth in ADPKD. Nat Rev Nephrol. 2009 Jun; 5(6):311-2.
Score: 0.012
-
Renal volume in children with ADPKD: size matters. Clin J Am Soc Nephrol. 2009 Apr; 4(4):698-9.
Score: 0.011
-
Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol. 2009 Mar; 4(3):560-6.
Score: 0.011
-
Nurturing passion in a time of academic climate change: the modern-day challenge of junior faculty development. Clin J Am Soc Nephrol. 2008 Nov; 3(6):1878-83.
Score: 0.011
-
Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol. 2008 Jul; 3(4):1197-204.
Score: 0.011
-
Treatment of autosomal dominant polycystic kidney disease (ADPKD): the new horizon for children with ADPKD. Pediatr Nephrol. 2008 Jul; 23(7):1029-36.
Score: 0.011
-
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008 Jan; 21(1):61-6.
Score: 0.010
-
Autosomal dominant polycystic kidney disease: time for a change? J Am Soc Nephrol. 2007 May; 18(5):1399-407.
Score: 0.010
-
Circulating microRNA Biomarkers of Thiazide Response in Hypertension. J Am Heart Assoc. 2024 Feb 20; 13(4):e032433.
Score: 0.008
-
Cystic and inherited kidney diseases. Am J Kidney Dis. 2003 Dec; 42(6):1305-17.
Score: 0.008
-
The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int. 2003 Nov; 64(5):1792-9.
Score: 0.008
-
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003 Sep; 64(3):1035-45.
Score: 0.008
-
Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation. Kidney Int. 2023 08; 104(2):334-342.
Score: 0.007
-
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial. Am J Kidney Dis. 2023 05; 81(5):517-527.e1.
Score: 0.007
-
Effects of Bardoxolone Methyl in Alport Syndrome. Clin J Am Soc Nephrol. 2022 12; 17(12):1763-1774.
Score: 0.007
-
Utilization of Cystatin C in the Outpatient Setting. Am J Nephrol. 2022; 53(7):534-541.
Score: 0.007
-
Health Disparities in Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States. Clin J Am Soc Nephrol. 2022 07; 17(7):976-985.
Score: 0.007
-
Predictors of antihypertensive response to a standard dose of hydrochlorothiazide for essential hypertension. Kidney Int. 2002 Mar; 61(3):1047-55.
Score: 0.007
-
Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2022 03; 17(3):374-384.
Score: 0.007
-
Pharmacogenomics of Hypertension in CKD: The CKD-PGX Study. Kidney360. 2022 02; 3(2):307-316.
Score: 0.007
-
Patient-reported outcome measures for pain in autosomal dominant polycystic kidney disease: A systematic review. PLoS One. 2021; 16(5):e0252479.
Score: 0.007
-
Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. Am J Nephrol. 2021; 52(3):180-189.
Score: 0.007
-
Sex Differences of Kidney Stone Urine Risk Factors after Roux-en-Y Gastric Bypass. Am J Nephrol. 2021; 52(2):173-176.
Score: 0.007
-
Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. Am J Med. 2021 07; 134(7):918-925.e2.
Score: 0.006
-
Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020 12 31; 16(1):48-58.
Score: 0.006
-
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores. CPT Pharmacometrics Syst Pharmacol. 2020 12; 9(12):678-685.
Score: 0.006
-
'A sword of Damocles': patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open. 2020 10 10; 10(10):e038005.
Score: 0.006
-
Mineral bone disease in autosomal dominant polycystic kidney disease. Kidney Int. 2021 04; 99(4):977-985.
Score: 0.006
-
Advancing Nephrology: Division Leaders Advise ASN. Clin J Am Soc Nephrol. 2021 02 08; 16(2):319-327.
Score: 0.006
-
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight. 2020 08 06; 5(15).
Score: 0.006
-
Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. Am J Kidney Dis. 2021 02; 77(2):255-263.
Score: 0.006
-
Interactions between FGF23 and Genotype in Autosomal Dominant Polycystic Kidney Disease. Kidney360. 2020 Jul; 1(7):648-656.
Score: 0.006
-
Expanded Imaging Classification of Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2020 07; 31(7):1640-1651.
Score: 0.006
-
Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. Am J Kidney Dis. 2020 09; 76(3):361-373.
Score: 0.006
-
Sorting nexin 1 loss results in increased oxidative stress and hypertension. FASEB J. 2020 06; 34(6):7941-7957.
Score: 0.006
-
Range and Variability of Outcomes Reported in Randomized Trials Conducted in Patients With Polycystic Kidney Disease: A Systematic Review. Am J Kidney Dis. 2020 08; 76(2):213-223.
Score: 0.006
-
Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. Am J Hypertens. 2020 02 22; 33(2):e2.
Score: 0.006
-
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 11 21; 9(1):17323.
Score: 0.006
-
Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney Int. 2020 02; 97(2):370-382.
Score: 0.006
-
Genome-Wide Meta-Analysis of Blood Pressure Response to ß1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019 08 20; 8(16):e013115.
Score: 0.006
-
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. Am J Hypertens. 2019 06 11; 32(7):668-675.
Score: 0.006
-
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans. Clin Transl Sci. 2019 09; 12(5):497-504.
Score: 0.006
-
Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2019 06 07; 14(6):823-833.
Score: 0.006
-
ß2 -Adrenergic Receptor Gene Affects the Heart Rate Response of ß-Blockers: Evidence From 3 Clinical Studies. J Clin Pharmacol. 2019 11; 59(11):1462-1470.
Score: 0.006
-
Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology (Carlton). 2019 Dec; 24(12):1214-1224.
Score: 0.006
-
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 07; 96(1):159-169.
Score: 0.006
-
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019 05; 95(5):1253-1261.
Score: 0.006
-
Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course. BMC Nephrol. 2019 02 25; 20(1):66.
Score: 0.006
-
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. Eur J Pharm Sci. 2019 Apr 01; 131:93-98.
Score: 0.006
-
Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. Pharmacogenet Genomics. 2019 01; 29(1):18-22.
Score: 0.006
-
Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol. 2018 12 27; 19(1):378.
Score: 0.006
-
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide. Pharmacogenet Genomics. 2018 11; 28(11):251-255.
Score: 0.006
-
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan. J Am Soc Nephrol. 2018 10; 29(10):2458-2470.
Score: 0.006
-
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genomics. 2018 Jun 20; 11(1):55.
Score: 0.005
-
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrol Dial Transplant. 2018 04 01; 33(4):645-652.
Score: 0.005
-
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.
Score: 0.005
-
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. J Am Heart Assoc. 2018 03 09; 7(6).
Score: 0.005
-
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant. 2018 03 01; 33(3):477-489.
Score: 0.005
-
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to ß-Blockers. J Am Heart Assoc. 2018 02 24; 7(5).
Score: 0.005
-
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials. Am J Kidney Dis. 2018 05; 71(5):666-676.
Score: 0.005
-
Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade? Curr Hypertens Rev. 2018; 14(1):39-47.
Score: 0.005
-
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. J Am Heart Assoc. 2017 12 29; 7(1).
Score: 0.005
-
Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2018 03; 93(3):691-699.
Score: 0.005
-
ADPKD Progression in Patients With No Apparent Family History and No Mutation Detected by Sanger Sequencing. Am J Kidney Dis. 2018 02; 71(2):294-296.
Score: 0.005
-
Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. Trials. 2017 Nov 23; 18(1):560.
Score: 0.005
-
Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. Sci Rep. 2017 11 22; 7(1):16068.
Score: 0.005
-
Development of the Autosomal Dominant Polycystic Kidney Disease Impact Scale: A New Health-Related Quality-of-Life Instrument. Am J Kidney Dis. 2018 02; 71(2):225-235.
Score: 0.005
-
Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2018 02; 29(2):571-578.
Score: 0.005
-
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 11 16; 377(20):1930-1942.
Score: 0.005
-
Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017 Nov 01; 32(11):1857-1865.
Score: 0.005
-
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. J Clin Hypertens (Greenwich). 2017 Dec; 19(12):1301-1308.
Score: 0.005
-
Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469.
Score: 0.005
-
Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 Jun 01; 32(6):969-975.
Score: 0.005
-
Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2017 11; 92(5):1206-1216.
Score: 0.005
-
Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant. 2017 03 01; 32(3):487-497.
Score: 0.005
-
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial. J Clin Pharmacol. 2017 07; 57(7):906-917.
Score: 0.005
-
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease. Am J Nephrol. 2017; 45(3):257-266.
Score: 0.005
-
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response. Circ Cardiovasc Genet. 2017 Jan; 10(1).
Score: 0.005
-
Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev. 2017; 13(2):109-120.
Score: 0.005
-
Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease. Am J Kidney Dis. 2017 03; 69(3):482-484.
Score: 0.005
-
Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017 02; 91(2):493-500.
Score: 0.005
-
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial. J Am Soc Nephrol. 2017 May; 28(5):1592-1602.
Score: 0.005
-
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial. Am J Kidney Dis. 2017 Feb; 69(2):210-219.
Score: 0.005
-
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. Hypertension. 2017 01; 69(1):51-59.
Score: 0.005
-
Automated segmentation of liver and liver cysts from bounded abdominal MR images in patients with autosomal dominant polycystic kidney disease. Phys Med Biol. 2016 11 21; 61(22):7864-7880.
Score: 0.005
-
Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. Am J Nephrol. 2016; 44(2):130-40.
Score: 0.005
-
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration. Hypertension. 2016 09; 68(3):621-9.
Score: 0.005
-
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension. Am J Hypertens. 2016 10; 29(10):1186-94.
Score: 0.005
-
Mutations in GANAB, Encoding the Glucosidase IIa Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. Am J Hum Genet. 2016 06 02; 98(6):1193-1207.
Score: 0.005
-
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial. Clin J Am Soc Nephrol. 2016 05 06; 11(5):803-811.
Score: 0.005
-
Predicted Mutation Strength of Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016 09; 27(9):2872-84.
Score: 0.005
-
Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2016 Apr 07; 11(4):576-84.
Score: 0.005
-
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to ß-Blockers in Hypertensive African Americans. Hypertension. 2016 Mar; 67(3):556-63.
Score: 0.005
-
Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. Nephrol Dial Transplant. 2016 11; 31(11):1887-1894.
Score: 0.005
-
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens. 2015 Nov; 33(11):2278-85.
Score: 0.005
-
Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis. 2015 Oct; 66(4):583-90.
Score: 0.004
-
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens. 2015 Jun; 33(6):1301-9.
Score: 0.004
-
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015 Jul; 88(1):146-51.
Score: 0.004
-
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. Metab Syndr Relat Disord. 2015 Jun; 13(5):195-202.
Score: 0.004
-
A novel simple method for determining CYP2D6 gene copy number and identifying allele(s) with duplication/multiplication. PLoS One. 2015; 10(1):e0113808.
Score: 0.004
-
Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015 Jan 26; 4(1):e001521.
Score: 0.004
-
Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2267-76.
Score: 0.004
-
Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014 Dec 11; 371(24):2255-66.
Score: 0.004
-
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014 Nov 10; 3(6):e001398.
Score: 0.004
-
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy. 2014 Nov; 34(11):1132-40.
Score: 0.004
-
Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol. 2015 Jan; 13(1):155-64.e6.
Score: 0.004
-
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015 Jan; 26(1):160-72.
Score: 0.004
-
Is diabetes mellitus-linked amino acid signature associated with ß-blocker-induced impaired fasting glucose? Circ Cardiovasc Genet. 2014 Apr; 7(2):199-205.
Score: 0.004
-
Novel methodology to evaluate renal cysts in polycystic kidney disease. Am J Nephrol. 2014; 39(3):210-7.
Score: 0.004
-
Baseline predictors of central aortic blood pressure: a PEAR substudy. J Am Soc Hypertens. 2014 Mar; 8(3):152-8.
Score: 0.004
-
Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 Feb; 9(2):406-15.
Score: 0.004
-
Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study. Am J Kidney Dis. 2014 Feb; 63(2):214-26.
Score: 0.004
-
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment. Pharmacotherapy. 2014 Feb; 34(2):123-30.
Score: 0.004
-
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. PLoS One. 2013; 8(10):e76984.
Score: 0.004
-
Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol. 2013; 38(4):333-41.
Score: 0.004
-
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013 Aug; 62(2):391-7.
Score: 0.004
-
The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension. Am J Hypertens. 2013 Aug; 26(8):957-64.
Score: 0.004
-
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. J Hypertens. 2013 Apr; 31(4):698-704.
Score: 0.004
-
Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2013 Jul; 8(7):1089-97.
Score: 0.004
-
Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013; 8(3):e57639.
Score: 0.004
-
Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals. PLoS One. 2013; 8(1):e52062.
Score: 0.004
-
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One. 2013; 8(1):e53016.
Score: 0.004
-
Response to genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2013 Jan; 61(1):e6.
Score: 0.004
-
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012 Dec 20; 367(25):2407-18.
Score: 0.004
-
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet. 2012 Dec; 5(6):686-91.
Score: 0.004
-
G protein receptor kinase 4 polymorphisms: ß-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension. 2012 Oct; 60(4):957-64.
Score: 0.004
-
Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. Kidney Blood Press Res. 2012; 35(6):477-82.
Score: 0.004
-
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker. Hypertension. 2012 Jun; 59(6):1204-11.
Score: 0.004
-
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med. 2012 Mar 22; 10:56.
Score: 0.004
-
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med. 2012 Mar 13; 10:47.
Score: 0.004
-
Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012 Apr; 81(8):784-90.
Score: 0.003
-
Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int. 2012 Mar; 81(6):577-85.
Score: 0.003
-
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens. 2012 Mar; 25(3):359-65.
Score: 0.003
-
Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2508-15.
Score: 0.003
-
Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol. 2011 Oct; 6(10):2499-507.
Score: 0.003
-
Nephrology fellows show consistent use of, and improved knowledge from, a nephrologist-programmed teaching instrument. J Nephrol. 2011 May-Jun; 24(3):345-50.
Score: 0.003
-
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis. 2011 May; 57(5):692-9.
Score: 0.003
-
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics. 2011 Jan; 21(1):42-9.
Score: 0.003
-
Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011 Mar; 6(3):640-7.
Score: 0.003
-
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010 Sep; 23(9):1014-22.
Score: 0.003
-
Lack of association between polymorphisms in STK39, a putative thiazide response gene, and blood pressure response to hydrochlorothiazide. Pharmacogenet Genomics. 2010 Aug; 20(8):516-9.
Score: 0.003
-
Renal CD14 expression correlates with the progression of cystic kidney disease. Kidney Int. 2010 Sep; 78(6):550-60.
Score: 0.003
-
Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol. 2010 Jul; 5(7):1312-29.
Score: 0.003
-
Renal arterial blood flow measurement by breath-held MRI: Accuracy in phantom scans and reproducibility in healthy subjects. Magn Reson Med. 2010 Apr; 63(4):940-50.
Score: 0.003
-
Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging. 2010 Feb; 31(2):440-6.
Score: 0.003
-
Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich). 2010 Jan; 12(1):14-21.
Score: 0.003
-
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension. 2010 Jan; 55(1):61-8.
Score: 0.003
-
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Pharmacotherapy. 2009 Oct; 29(10):1157-65.
Score: 0.003
-
Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study. Physiol Genomics. 2009 Sep 09; 39(1):56-60.
Score: 0.003
-
MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol. 2009 Apr; 4(4):719-25.
Score: 0.003
-
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009 Mar; 157(3):442-9.
Score: 0.003
-
Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome. Kidney Int. 2008 Dec; 74(11):1468-79.
Score: 0.003
-
Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension. 2008 Aug; 52(2):359-65.
Score: 0.003
-
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2007 Jul; 18(7):2143-60.
Score: 0.003
-
Controversies in renal artery stenosis: a review by the American Society of Nephrology Advisory Group on Hypertension. Am J Nephrol. 2007; 27(2):212-20.
Score: 0.002
-
Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2007 Jan; 2(1):112-20.
Score: 0.002
-
Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006 Nov; 17(11):3013-9.
Score: 0.002
-
Volume progression in polycystic kidney disease. N Engl J Med. 2006 May 18; 354(20):2122-30.
Score: 0.002
-
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort. J Am Soc Nephrol. 2006 Mar; 17(3):854-62.
Score: 0.002
-
Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis. 2005 Dec; 46(6):1058-64.
Score: 0.002
-
Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006 Jan; 1(1):64-9.
Score: 0.002
-
Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006 Jan; 1(1):148-57.
Score: 0.002
-
WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension. 2005 Oct; 46(4):758-65.
Score: 0.002
-
Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects. Am J Hypertens. 2005 Aug; 18(8):1077-83.
Score: 0.002
-
A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide. Pharmacogenet Genomics. 2005 May; 15(5):287-93.
Score: 0.002
-
Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens. 2005 Mar; 18(3):398-402.
Score: 0.002
-
Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 Dec; 64(6):2214-21.
Score: 0.002
-
Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens. 2003 Oct; 16(10):834-9.
Score: 0.002
-
Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease. Kidney Int. 2003 May; 63(5):1824-30.
Score: 0.002
-
Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int. 2002 Nov; 62(5):1718-23.
Score: 0.002
-
Screening for primary aldosteronism: implications of an increased plasma aldosterone/renin ratio. Clin Chem. 2002 Nov; 48(11):1919-23.
Score: 0.002
-
Reproducibility of blood pressure response to hydrochlorothiazide. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):408-12.
Score: 0.002
-
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol. 2002 Jul; 13(7):1733-9.
Score: 0.002